Category Archives: Biochemistry

Cortez named interim chair in the Department of Biochemistry; York named Impossible Foods chief science officer – Vanderbilt University News

David Cortez, Richard N. ArmstrongChairforInnovation inBiochemistryandprofessor of biochemistry, has been named interimchairintheDepartment ofBiochemistrybeginningJan. 1.

This follows the departure of John York, who was recently named chief science officer of food technology startup Impossible Foods and will be moving to California.

The investments that Dr. York directed into the infrastructure, training and people in the Department of Biochemistry have been transformative. Simply put, I want to build on this momentum, Cortez said. I look forward to working with the faculty, staff and trainees to continue our shared pursuit of excellence in science discovery and education. The people in this department and at Vanderbilt make it special, and I will do everything I can to support them as they pursue their goals.

Cortez, also associate director for basic sciences research at theVanderbilt-Ingram Cancer Center, specializes in understanding the function of DNA damage response pathways in maintaining a healthy genome, and in understanding how those pathways are activated. His labs current projects include identifying new proteins involved in DNA damage response and developing cancer therapeutics that target that response. The trans-institutional Cortez lab is connected to theGenome Maintenance Research Programwithin the VICC,the Center in Molecular Toxicology,Vanderbilt Institute of Chemical Biologyand the Department of Biochemistry.

During Yorks tenure, the Department of Biochemistry became 2019s top NIH-funded department in the nation.

During Yorks tenure, the Department of Biochemistry became 2019s top NIH-funded department in the nation. With an expanded and diversified faculty, he invigorated the graduate and development research programs, building a shared sense of purpose and community in the department. These efforts fostered an environment that supports discovery science and curiosity-driven research, saidLawrence Marnett, dean of School of Medicine Basic Sciences.

My time at Vanderbilt has been a remarkable professional experience and a tremendous privilege. Together, we have built a discovery-science environment for recruitment of diverse faculty and trainees, York said. The commitment to academic excellence and pursuit of transformative solutions to problems facing the world shared by my colleagues and students is unparalleled, and the department is well-positioned to continue its steep upward trajectory. Iintend to maintain the One Vanderbilt spirit of collaboration in the next phase of my career and will remain a friend to all the wonderful colleagues I have worked with over the past nine years.

It has been an honor to work with John, who not only significantly increased funding for the Department of Biochemistry, but has also helped to establish Vanderbilt as a top destination for world-class faculty and scholars determined to make life-changing discoveries, said Provost and Vice Chancellor for Academic AffairsSusan R. Wente. I wish him luck with his next venture and am confident that David Cortez has the dedication and the visionary leadership to continue the remarkable momentum that John has established.

Cortez graduated summa cum laude from the University of Illinois at Champaign-Urbana with highest honors in biology and biochemistry and received his Ph.D. in molecular cancer biology from Duke University. After postdoctoral training as a Jane Coffin Childs Fellow with Stephen Elledge at the Baylor College of Medicine, he joined Vanderbilt in 2002. In 2009, Cortez was named professor of biochemistry and Ingram Professor of Cancer Research. His achievements have been recognized with the Howard Temin Award from the National Cancer Institute, the Wilson S. Stone Memorial Award from the MD Anderson Cancer Center and a Pew Scholar Award from the Pew Charitable Trusts. Cortez is a member of the editorial boards of the journalsCell ReportsandScience Advances, and in 2017 he was named a fellow of the American Association for the Advancement of Science.

While the departure of an esteemed colleague is never good news, we are proud of what John has built and wish him well in this exciting new endeavor. Our biochemistry students and faculty have benefitted tremendously from the hard work and dedication that John brought to his role, Marnett said. We are also extremely fortunate to have a world-class scientist like Dave Cortez assume the leadership of the department and continue its momentum. I look forward to working with him and anticipate he will be very successful.

Read this article:
Cortez named interim chair in the Department of Biochemistry; York named Impossible Foods chief science officer - Vanderbilt University News

Impossible Foods Accelerates Innovation Strategy With New Hire – Progressive Grocer

Impossible Foods continues to accelerate its innovation strategy with its new hire of Vanderbilt University Biochemistry Department Chair Dr. John D. York, Ph.D., as chief science officer. The company plans to double the number of scientistson its team within a year as part of its plan to heavily invest in R&D.

The privately held food tech startup was founded in 2011 by Dr. Patrick O. Brown, M.D., Ph.D., professor emeritus of biochemistry at Stanford University, and a former Howard Hughes Medical Institute investigator, as a way to develop nutritious meat and dairy products from plants with a much smaller environmental footprint than meat from animals.

Impossible Foods scientists best-known achievement to date is the ImpossibleBurger. Impossible Foods first launched its plant-based Impossible Burger in retail stores in September 2019, and only a year later the product has expanded its reach to big retail names like Albertsons, The Kroger Co., Traders Joesand Walmart.

Under Yorks leadership, Impossible Foods will continue to build its food technology platform and expand basic research capabilities to accelerate next-generation plant-based products such as Impossible Pork, milk, steak and other foods.

Yorks first day at Redwood City, California-basedImpossible Foods will be Jan. 4. He will serve on Impossible Foods senior leadership team and oversee research and development, and product innovation. He will report directly to Brown, the company's CEO.

Throughout his career, John has contributed to discoveries in biochemistry thanks to his curiosity and risk tolerance, said Brown. Just as important, hes a proven and strong mentor and team leader. Im confident that John will make an immediate, positive contribution and quickly become an inspiring role model within our expanding R&D team.

York, a former Investigator for the Howard Hughes Medical Institute, has led the Department of Biochemistry at Vanderbilt University since 2012. His team paved the way for discoveries in protein structure and function, cell signaling and molecular genetics. The Midwest native received his undergraduate degree from the University of Iowa and his Ph.D. in molecular cell biology and biochemistry from Washington University, in Saint Louis.

The opportunity to use biochemistry to save the planet is a spectacular motivation, York said. That Impossible Foods is rooted in discovery science and engineering as a key innovation platform resonates with my core values and lifelong pursuits in research. Its an honor and privilege to be part of the team, and I look forward to the limitless future possibilities.

Impossible Foods intellectual property encompasses how to replicate the sensory experience of animal-derived meat, including how it tastes, cooks, sizzles and smells.

The company has raised approximately $1.5 billion since its founding in 2011, including $700 million in two rounds this year.The plant-based company said that it raised $200 million in its funding round in August led by New York-based new investor Coatue.

Other investors include Mirae Asset Global Investments, Khosla Ventures, Bill Gates, Google Ventures, Horizons Ventures, UBS, Viking Global Investors, Temasek, Sailing Capital and Open Philanthropy Project.

Further, Impossible Foods has been keeping busy during the pandemic, filling the needs of a growing plant-based category after retailers experienced meat shortages during the height ofpandemic stockpiling. It even entered the direct-to-consumer space with an e-commerce site,indicatingthat DTC is a natural fit for this pandemic worldas consumer behavior shifts.

Go here to read the rest:
Impossible Foods Accelerates Innovation Strategy With New Hire - Progressive Grocer

Immunovia to Host a Third Webinar in the Series on IMMray PanCan-d: Verification Study and Clinical Use – PRNewswire

LUND, Sweden, Dec. 11, 2020 /PRNewswire/ --Immunovia AB (publ)("Immunovia"), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray for the early detection of cancer,today announced that the company will be hosting the third webinar in the series on IMMray PanCan-d, Immunovia's test for early detection of pancreatic cancer. This third webinar will cover IMMray

PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases.

Event Details: Webinar No. 3:Immunovia's IMMray PanCan-d Webinar Series Verification Study and Clinical Use

Date and Time: December 17, 2020 at 15:00 CET

Moderator for the Webinar is CEO Patrik Dahlen

Presenters:Thomas King, MD, PhD, Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia

Immediately after the webinar, the Immunovia team will host a live Q&A session.

Webinar login and access details will be released on Monday Dec 14, 2020.

About the presenters:

Dr. Thomas King, Medical Director, Immunovia

Dr. King is a board-certified MD Pathologist with a PhD in Molecular Biology also from Washington University in St. Louis. Dr. King also has extensive experience as a Laboratory Director in hospital, academic and corporate settings in New England. He has deep expertise in laboratory administration and automation, surgical pathology, and molecular pathology and is currently an Adjunct Associate Professor in the School of Health Professions, Rutgers University.

Dr. Linda Mellby, VP Research & Development, Immunovia

Dr. Mellby received her PhD in Immunotechnology from the Department of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, and a MSc in Chemistry Engineering. Mellby has 15+ years of experience in recombinant antibody microarray technology, Immunovia's IMMrayplatform. Additionally, she has deep knowledge on platform features, technology development, as well as, clinical applications within oncoproteomics and autoimmunity.

Dr. Laura Chirica, Chief Commercial Officer, Immunovia

Dr. Chirica received her PhD in Biochemistry from Ume University, Sweden, and a MSc in Biochemistry and a BSc in Biotechnology. With more than 15+ years of experiences in leading commercial positions within the life science and diagnostics industry, Dr. Chirica contributes with extensive experience in business, organization and strategic development, sales, strategic and tactical marketing, product management and product support. She has a track record of leading and restructuring international sales and marketing organizations, driving business development, champion integration of acquired companies as well as developing branding and market communication platforms.

For more information, please contact:

Patrik Dahlen, CEO Immunovia

Email: [emailprotected]

Tel: +46 73 376 76 64

About Immunovia

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based onImmunovia's proprietary test platform called IMMray.Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and groundbreaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray PanCan-d, is undergoing clinical evaluation in some of theworld's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.

When validated, IMMray PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visitwww.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-third-webinar-in-the-series-on-immray--pancan-d--verification-study-and-clinical,c3253308

The following files are available for download:

SOURCE Immunovia AB

Read this article:
Immunovia to Host a Third Webinar in the Series on IMMray PanCan-d: Verification Study and Clinical Use - PRNewswire

Global Warming Solutions Inc. to move its headquarters to Temecula, California in January 2021 – GlobeNewswire

Jacksonville, Florida , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Global Warming Solutions Inc. (OTC MARKET: GWSO) - a developer of technologies aimed at mitigating the effects of global warming - today announced that the Board of Directors have made a decision to locate their headquartersto Temecula, California in January 2021.

In announcing the states new100% zero-emission vehiclesfor new car and SUV sales goal by 2035, Governor Newsom said electric vehicles are thenext big global industryand California wants to dominate it.

The Electric Vehicle (EV) industry growth in California has positioned the state as a globally leading researcher, designer, manufacturer and exporter of transportation-related products, services and technologies, creating 275,600 direct EV industry jobs statewide and shifting the EV industrys U.S. footprint from Michigan to California.

We are excited to have a Companys Headquarter in Southern California. This is a perfect place to grow our EV business. Our new headquarter will have a showroom, research lab and warehouse space, said Vladimir Vasilenko, CEO of Global Warming Solutions, Inc.

The Company also welcome Joseph Patterson to its Advisory Committee.

Joseph L. Patterson holds a BS is in Experimental Psychology and Biochemistry from the University of Sioux Falls, South Dakota, and a Masters in Biophysics and Physiology from Georgetown University in Washington D.C.

Joseph is a tech and data-centric marketing executive in the Martech/ Adtech space at Claritas, a leading data-driven marketing company based out of Cincinnati. At Claritas, he executes product positioning, messaging, and go-to-market strategies for their unique data and proprietary identity-based market research solutions. He also drives lead generation programs to meet pipeline targets, while closely monitoring and optimizing campaign performance, conversion rates, quarterly targets, and overall funnel health. Before Claritas, Joseph was VP of Marketing at Geoscape, a SaaS marketing intelligence company that got acquired by Claritas back in 2018, a company that provided geo-demographic market intelligence and consulting to Fortune 500 clients. Before that, Joseph was the highest-ranking corporate marketing officer at an alternative financial technology startup that got acquired 14 months after he came on board.

In a separate matter, GWSO received a proposal from several private investors to invest directly into the Company. "The fact that accredited investors are willing to invest in our companys growth affords us even more opportunities to deliver positive results. The Company will update our shareholders on the outcome of the negotiations," stated Vladimir Vasilenko, CEO of Global Warming Solutions, Inc.

To learn more about Global Warming Solutions, Inc. Visit:http://www.gwsogroup.com

Forward-Looking Statements

This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent the Companys current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Companys management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: potential, expect, look forward, believe, dedicated, building, or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by the Company herein are often discussed in filings the Company makes with the United States Securities and Exchange Commission (SEC) available atwww.sec.govand on the Companys website athttps://www.gwsogroup.com.

Contact:

Vladimir VasilenkoCEOGlobal Warming Solutions, Inc.Vladimir@gwsogroup.com

Go here to read the rest:
Global Warming Solutions Inc. to move its headquarters to Temecula, California in January 2021 - GlobeNewswire

Excerpt: A Reply to Michael Ruse – Discovery Institute

Photo: Michael Behe speaking at the 2020 Dallas Conference on Science & Faith, by Chris Morgan.

Editors note: We are delighted to celebrate the publication of the new bookA Mousetrap for Darwin: Michael J. Behe Answers His Critics. What follows is an excerpt: A Reply to Michael Ruse,Research News & Opportunity in Science and Theology(July/August 2002).

Authors note: This article appeared in a discussion of intelligent design published inResearch News & Opportunity in Science and Theology(now discontinued). Other contributors included Karl Giberson, Michael Ruse, Eugenie Scott, William Dembski, Robert Pennock, and Jonathan Wells. Philosopher Ruse unwisely stepped out of his area of expertise to weigh in on a scientific dispute between Russell Doolittle and myself.

If nothing else, Michael Ruse has chutzpah.

Let me tell a little story about blood clotting, Russell Doolittle, and Michael Ruse. In 1996, inDarwins Black Box, I argued (notoriously) that the blood clotting cascade is irreducibly complex (that is, if a part is removed the cascade doesnt work), and so is a problem for Darwinian evolution and is better explained by intelligent design. However, Russell Doolittle professor of biochemistry at the University of California, San Diego, member of the National Academy of Sciences, and lifelong student of the blood clotting system disagreed. Writing in 1997 inBoston Review, a publication of MIT, Doolittle pointed to a then-recent report which, he claimed, showed that several parts of the clotting system plasminogen and fibrinogen could be knocked out of mice without ill effect. (Fibrinogen is the fabric of the clot. Plasminogen removes clots once healing is complete.) According to Professor Doolittle, if one component is removed, the mice are in bad shape, but if two components are removed, the mice were normal.1 While that would be an interesting result, its incorrect. Doolittle misread the report.

The authors of the paper wrote in their abstract that Mice deficient in plasminogen and fibrinogen are phenotypically indistinguishable from fibrinogen-deficient mice.2In other words, mice lacking both components have all the problems that mice lacking just fibrinogen have. Those problems include failure to clot, hemorrhage, and death of females during pregnancy. The mice are very far from normal. They are decidedly not promising evolutionary intermediates.

A year later, apparently unaware of Doolittles mistake, Ruse instructed the readers ofFree Inquiryon why intelligent design proponents are scorned.

For example, Behe is a real scientist, but this case for the impossibility of a small-step natural origin of biological complexity has been trampled upon contemptuously by the scientists working in the field. They think his grasp of the pertinent science is weak and his knowledge of the literature curiously (although conveniently) outdated. For example, far from the evolution of clotting being a mystery, the past three decades of work by Russell Doolittle and others has thrown significant light on the ways in which clotting came into being. More than this, it can be shown that the clotting mechanism does not have to be a one-step phenomenon with everything already in place and functioning. One step in the cascade involves fibrinogen, required for clotting, and another, plaminogen [sic], required for clearing clots away.3

And Ruse went on to quote the passage from Doolittle I quoted above. Ruse was so impressed with Doolittles work that he evencopied his typo/misspelling, plaminogen. Let me state clearly what this means. Ruse is a prominent academic Darwinian philosopher. Yet he apparently didnt even bother to look up and understand the original paper on the hemorrhaging mice before deciding Doolittle was right and I was contemptibly wrong. To this day he takes sides in a scientific dispute he shows no signs of understanding.

But perchance Ruse is so confident because the rest of the scientific community agrees with Doolittle (how does Ruse know this?) that Im simply not up to date. Well, maybe many scientists do agree with Doolittle. But those who do are as wrong as he was. In my travels Ive had quite a few scientists sneeringly throw his erroneousBoston Review argument at me. Just recently Neil S. Greenspan, a professor of pathology at Case Western Reserve University, wrote inThe Scientist, The Design advocates also ignore the accumulating examples of the reducibility of biological systems. As Russell Doolittle has noted in commenting on the writings of one ID advocate4and Greenspan goes on to approvingly cite Doolittles mistaken argument inBoston Review.

Then with innocent irony Greenspan continues, These results cast doubt on the claim by proponents of ID that they know which systems exhibit irreducible complexity and which do not. But since the results of the hemorrhaging-mice study were precisely the opposite of what Doolittle along with Ruse, Greenspan, and other copycats thought, the shoe is on the other foot. The Doolittle incident shows that Darwinists in fact dont know how natural selection could assemble complex biochemical systems. Worse, it shows that they either cannot or will not recognize problems for their theory.

Ill bet a philosopher like Ruse could think of some other reasons why a lot of the scientific community is up in arms over intelligent design besides spurious claims that we fail to understand the workings of evolution.

Read more from the original source:
Excerpt: A Reply to Michael Ruse - Discovery Institute

KGH, Andhra Medical College in Vizag to be revamped with Rs 500 crore – YoVizag

Age-old medical institutions in Vizag King George Hospital (KGH) and Andhra Medical College (AMC) are all set to receive a facelift under the Nadu-Nedu programme of the Andhra Pradesh state government. On Friday, during a meeting held at the AMC Principals office in Vizag, it was revealed that the infrastructure of the college, as well as the hospital, will be revived with a budget of Rs 500 crore.

Reportedly, the current Out-Patient, Cardiology, Cardiothoracic, Orthopaedic, Surgery, Radiology, and Obstetrics blocks at the hospital will be pulled down. Likewise, the existing buildings of Biochemistry and Pharmaceulogy departments at the AMC will be dismantled in order to make space for the new constructions. The officials are reportedly chalking out plans to build five new blocks to facilitate the aforementioned departments with state-of-the-art technology. While two of the blocks will be seven-storeyed buildings, the rest of them will be five-storeyed structures.

While the date of commencement of the project has not been announced, it was informed that the Obstetrics, Cardiology, Cardiothoracic, and Orthopaedic departments will be temporarily shifted to the VIMS Hospital after the construction activities begin at the KGH and Andhra Medical College in Vizag. As many as 500 beds from the KGH are likely to be shifted to the VIMS Vizag.

It is to be noted that the Surgery, Radiology, Biochemistry, and Pharmaceulogy departments will be temporarily operated from the newly built CSR Block at the KGH. The authorities have also decided to improve the green cover by planting saplings and developing gardens in place of the existing Outpatient and Medical blocks. However, the older buildings at the KGH and Andhra Medical College in Vizag, which were constructed during the colonial rule in Vizag, will not be modified under the Nadu-Nedu programme.

Andhra Pradesh state government launched Nadu-Nedu scheme to improve the basic infrastructure at schools and Anganwadis. Earlier in February, Andhra Pradesh Chief Minister, YS Jagan Mohan Reddy extended this initiative to modernise all the government hospitals within three years. Briefing the importance of the Nadu-Nedu programme in the health sector, Chief Minister mentioned that this scheme will be helpful in strengthening the public healthcare system in the state.

Original post:
KGH, Andhra Medical College in Vizag to be revamped with Rs 500 crore - YoVizag

Fully Automatic Biochemistry Analyzer Market Size 2020 Global Analysis, Trends, Forecast up to 2027 – Cheshire Media

What are the emerging opportunities in the Fully Automatic Biochemistry Analyzer Market?

Currently, significant business sectors are going through changes. This has prompted huge benefits for a few and misfortunes for other people. To make the most out of the emerging chances, you can exploit the most granted Fully Automatic Biochemistry Analyzer market report. It offers nitty-gritty experiences into the market. This will doubtlessly manage their organizations in creating the following move over the impending industry quarters.

It must be noticed that the Fully Automatic Biochemistry Analyzer market is encountering unexpected ascent in reception by numerous new players (from MNCs to SMEs). It is because of the way that even with the market turbulences the Global market came out with solid numbers. With the new business running into the market, it is basic to stand apart from the group. The customers can undoubtedly accomplish this utilizing the means referenced in the Fully Automatic Biochemistry Analyzer market report.

What type of investigation is done in the Fully Automatic Biochemistry Analyzer market report?

Analysis of various socioeconomics for venturing into the market is important as it will hugely affect the development throughout the following coming years. The Fully Automatic Biochemistry Analyzer market report is planned subsequent to doing long periods of exploration and the information sifted through in the report was gathered from dependable sources, for example, government sites.

As the market is gigantic, it turns out to be imperative to comprehend the market from its underlying foundations. Get a superior perspective on the Fully Automatic Biochemistry Analyzer market through the data referenced in the committed areas of the report. With this, the customers likewise get a perspective on the business structure of the contenders.

What are the reasons that impact the growth of the Fully Automatic Biochemistry Analyzer Market?

As of late, the advanced transformation has pushed the associations in changing into a computerized business for coming to the intended interest group present over the globe. The Fully Automatic Biochemistry Analyzer market report shares the significance of neighborhood language, partners, and political situation that will drive the Global market higher than ever.

With the best possible comprehension of the Fully Automatic Biochemistry Analyzer market, the associations can hop onto the open doors that will bring productive outcomes. The customers can exploit the biggest in-house information base for taking the most effective actions. Likewise, the Fully Automatic Biochemistry Analyzer market report has committed segments covering the insights concerning the current market players. With the information on how they function and accomplish their objectives, your business can likewise be formed as needs be.

What type of analysis short-term or long-term is added in the Fully Automatic Biochemistry Analyzer Market report?

This is important to sidestep any negative circumstances that may affect the development of the organizations. In addition, the associations need to comprehend Porters five powers that shape the market elements. In the event that the customers wish to add or eliminate the names of the organizations, it tends to be done, to suit the desires for the clients, for accomplishing long-haul objectives. SWOT investigation helps in uncovering the qualities and shortcomings of the business. The PESTLE investigation helps in checking the outer elements that shape the market overall. Subsequently, for making a name in the Fully Automatic Biochemistry Analyzer market, it gets important to get thought from both SWOT and PESTLE investigations.

The Fully Automatic Biochemistry Analyzer market report likewise brushes over the significance of language and partners for the smooth working of the associations. Thusly, the customers are stacked with data and steps and are prepared to move into the market for accomplishing the ideal objectives.

About Us:

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Reports provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Read more:
Fully Automatic Biochemistry Analyzer Market Size 2020 Global Analysis, Trends, Forecast up to 2027 - Cheshire Media

Biochemistry Analyzer Market Incredible Possibilities, Growth Analysis and Forecast To 2028 ELITechGroup, EKF Diagnostics, Spinreact, Mindray – The…

Overview Of Biochemistry Analyzer Industry 2020-2028:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Biochemistry Analyzer Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Biochemistry Analyzer Market competition by top manufacturers as follow: URIT Medical Electronic, ELITechGroup, EKF Diagnostics, Spinreact, Mindray, Danaher, Roche Diagnostics

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/210314

The global Biochemistry Analyzer market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are:

Semi-Automatic Biochemical Analyzers

Fully Automated Biochemistry Analyzers

Market Segment by Applications, covers:

Academic Research Institutes

Biotechnology Companies

Contract Research Organizations

Diagnostic Centres

Hospitals

Pharmaceutical Companies

Others

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/210314

The analysis objectives of the report are:

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Biochemistry-Analyzer-Market-210314

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Read more:
Biochemistry Analyzer Market Incredible Possibilities, Growth Analysis and Forecast To 2028 ELITechGroup, EKF Diagnostics, Spinreact, Mindray - The...

AU may employ people to remind others of COVID guidelines – The Auburn Plainsman

Provost Bill Hardgrave met with faculty for a virtual town hall on Thursday via Zoom ahead of a spring semester professors feel will be challenging because of increased face-to-face classes.

Hardgrave proposed enlisting student workers and faculty to supervise campus to remind people to adhere to Auburn's COVID-19 guidelines, which he termed "hall monitors." Hardgrave said he and members of the University's Faculty Senate Executive Committee came up with the idea after listening to concerns about the spring semester.

"We will put people in the buildings if that's what it takes," Hardgrave said. "If we need be, [we'd] have people in there for the entire semester ... to keep the traffic flowing, keep people wearing their masks, keep them spaced out and going in and out the right doors."

Hardgrave intends to walk by every classroom in every academic building on campus for at least the first week of instruction in January to check that classes are running smoothly.

"We will take corrective action immediately during that first few weeks, and we'll continue that throughout the semester," he said.

Faculty had many questions about the proposal and student and faculty safety. Vanessa Falcao, chemistry and biochemistry lecturer, expressed concern about how about 200 students will transition in and out of her classes in close quarters with one another.

"[Students] have only 10 minutes to exchange between classes," Falcao said. "Is there any [thought] being put into extending the 10 minutes or how to organize to make the exchange of students safe with social distancing and lines?"

Hardgrave said the University considered extending the time between classes but felt the decision was "unwieldy." This is where hallway supervision might come into play, he said.

"These are the type of areas that we want to make sure we have these hall monitors ... who are going to make sure that people are coming in and out of the right doors, that they're coming in and out in an orderly fashion [and] that people aren't sitting along the walls congregated waiting to come in," Hardgrave said.

The provost said instructors might still need to be flexible in where they begin and end face-to-face classes to ensure students can safely enter rooms in time.

Some faculty questioned the ethics of having "hall monitors" in campus buildings.

"I do not think that people who are not trained health experts should be evaluating the green screens of the GuideSafe program or checking symptoms, and I worry about the unevenness of enforcing masks," said Sam Sommers, lecturer in the department of English. "How will they be trained? How will they be compensated for their labor? What is the plan?"

Hardgrave responded by saying that hall monitors would only be serving to encourage people to follow guidelines, and they would not ask about symptoms. Checking GuideSafe Healthcheck screener results, he said, is not something that requires medical training, and hall monitors would be tasked with directing people flagged as potentially exposed elsewhere.

"We have not worked out all the details, but we will have people in those classroom buildings," Hardgrave said. "We will hire people. It could be ... student workers [or] it could be that we ask for volunteers from our staff and our faculty to serve at certain hours of the day."

Hardgrave said faculty should control mask use in classrooms in their classes, as this doesn't fall under the provost's jurisdiction.

"I would treat wearing a mask the same as if they were talking on the phone while they were in the class," Hardgrave said to faculty in the meeting. "They are, by not wearing a mask, disrupting the class, and you need to treat it accordingly."

Hardgrave said Bobby Woodard, senior vice president of Student Affairs, told him that there haven't been any student conduct issues of students not wearing masks in classrooms.

There were situations, the provost said, where instructors felt uneasy directing students to put on a face mask. Hardgrave said that next semester, faculty should ask students to wear masks even if it means interrupting class. If students refuse, he said they should be asked to leave unless they have medical documentation stating they are unable to wear a face covering.

Other faculty were skeptical about the effectiveness of having "hall monitors" based on behavior they saw during the fall semester with fewer students on campus. Jaena Alabi, English and psychology librarian, said from Sept. 17 to Oct. 21, Ralph Brown Draughon Library staff recorded asking people 30,000 times to put a mask on or to wear them correctly.

"We've got two areas in particular we've got to monitor one is the library, the other is the Student Center," Hardgrave said. "We've got to work on those areas. Some of you may disagree with this, but I think for the most part, our students did very well on wearing their masks. I think trust is a really key element but ... I think creating a culture of compliance is important."

Here is the original post:
AU may employ people to remind others of COVID guidelines - The Auburn Plainsman

Immunomic Therapeutics’ CEO to Present at the 2nd Annual Glioblastoma Drug Development Summit – Business Wire

ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 2nd Annual Glioblastoma Drug Development Virtual Summit. On Wednesday, December 9th, Chief Executive Officer at ITI, Dr. Bill Hearl, will be presenting a talk titled, Adaptive T-cell Immunotherapy for Newly Diagnosed Glioblastoma: Using Targeted Antigen Presentation to Enhance Immune Responses. Dr. Hearl will discuss ITIs investigational platform technology, the companys lead program and its preliminary data in GBM, as well as the companys future focus.

Presentation details are as follows:

Title: Adaptive T-cell Immunotherapy for Newly Diagnosed Glioblastoma: Using Targeted Antigen Presentation to Enhance Immune Responses

Presentation Category: Vaccines

Date and Time: Wednesday, December 9, 2020 12:40 PM EST / 9:40 AM PDT

Location: Virtual Summit

About UNITE

ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein 1, an endogenous protein in humans, for immune processing. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach puts UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that have the potential to generate broad immune responses. The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including targeting viral antigens, cancer antigens, neoantigens and producing antigen-derived antibodies as biologics. In early 2020, an investment of over $60M by HLB Co., LTD, a global pharmaceutical company, enabled ITI to accelerate application of its immuno-oncology platform, in particular to glioblastoma multiforme, and rapidly advance other key candidates in the pipeline, including the most recent initiative into infectious diseases with development of its vaccine candidate for COVID-19. The Company has built a large pipeline from UNITE with eight oncology programs, multiple animal health programs and a SARS-CoV-2 program to prevent and treat COVID-19. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Duke University and the University of Florida. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit http://www.immunomix.com.

Read more here:
Immunomic Therapeutics' CEO to Present at the 2nd Annual Glioblastoma Drug Development Summit - Business Wire